Bezafibrate ameliorates diabetes and may benefit patients with nonalcoholic fatty liver disease and impaired glucose metabolism by reducing steatosis, enhancing hepatic mitochondrial mass, improving metabolic flexibility, and increasing hepatic insulin sensitivity (Franko et al., 2017). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.